GlassScriptPhysician profile
Donald R Lovelace
NPI 1780648972
$1,098.46
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $159 · 2021: $389 · 2022: $227.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $154.70 | 2020-2022 | |
| Abbvie INC. | $150.42 | 2019-2021 | |
| Coopersurgical, INC. | $100.72 | 2021 | |
| Teleflex LLC | $93.86 | 2021 | |
| Amag Pharmaceuticals, INC. | $89.32 | 2019 | |
| Intuitive Surgical, INC. | $71.43 | 2022 | |
| Pfizer INC. | $58.20 | 2019-2021 | |
| Allergan, INC. | $52.21 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.00 | 2019-2020 | |
| Aspira Women'S Health INC | $41.67 | 2022 | |
| Exeltis, USA INC. | $40.41 | 2022 | |
| Amgen INC. | $39.90 | 2019-2020 | |
| Duchesnay USA Incorporated | $38.62 | 2019 | |
| Astellas Pharma US INC | $33.17 | 2019-2022 | |
| Avion Pharmaceuticals | $31.02 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $14.50 | 2019 | |
| Ethicon US, LLC | $13.79 | 2019 | |
| Evofem Biosciences, INC. | $12.24 | 2021 | |
| Lupin INC. | $11.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Lovelace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.